ReviewF1000prime reports2014
Recent advances in our understanding of Streptococcus pneumoniae infection.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Coptis rhizome extract influence on Streptococcus pneumoniae through autolysin activation.AMB Express · 2024Article
- Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older.Applied health economics and health policy · 2024Article
- Necrotizing Pneumonia in Children: Early Recognition and Management.Journal of clinical medicine · 2023Review
- Characterization of the innate immune response to Streptococcus pneumoniae infection in zebrafish.PLoS genetics · 2023Article
- Invasive pneumococcal disease burden in hospitalized adults in Bogota, Colombia.BMC infectious diseases · 2021Observational
- Article
- HIF-1α is involved in blood-brain barrier dysfunction and paracellular migration of bacteria in pneumococcal meningitis.Acta neuropathologica · 2020Article
- Interleukin 17 Receptor E (IL-17RE) and IL-17C Mediate the Recruitment of Neutrophils during AcuteInfection and immunity · 2019Article
- Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia.Journal of clinical medicine · 2019Article
- Article
- Current Perspectives on Treatment of Gram-Positive Infections in India: What Is the Way Forward?Interdisciplinary perspectives on infectious diseases · 2019Review
- Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging.Medical sciences (Basel, Switzerland) · 2018Review
- The Role of Cadaverine Synthesis on Pneumococcal Capsule and Protein Expression.Medical sciences (Basel, Switzerland) · 2018Article
- Article
- The Metabolic Sensor GPR43 Receptor Plays a Role in the Control ofFrontiers in immunology · 2018Article
- Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling.American journal of respiratory and critical care medicine · 2017Article
- Evaluation of Two Supplemented Culture Media for Long-Term, Room-Temperature Preservation ofBioMed research international · 2017Article
- Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia.PloS one · 2017Article
- Surveillance of pneumococcal diseases in Central and Eastern Europe.Human vaccines & immunotherapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of significant challenges remain with regard to the diagnosis, treatment, and prevention of infections with Streptococcus pneumoniae (pneumococcus), which remains the most common bacterial cause of community-acquired pneumonia. Although this infection is documented to be extremely common in younger children and in older adults, the burden of pneumonia it causes is considerably underestimated, since the incidence statistics are derived largely from bacteremic infections, because they are easy to document, and yet the greater burden of pneumococcal pneumonias is non-invasive. It has been estimated that for every bacteremic pneumonia that is documented, three non-bacteremic infections occur. Management of these infections is potentially complicated by the increasing resistance of the isolates to the commonly used antibiotics. Furthermore, it is well recognized that despite advances in medical care, the mortality of bacteremic pneumococcal pneumonia has remained largely unchanged over the past 50 years and averages approximately 12%. Much recent research interest in the field of pneumococcal infections has focused on important virulence factors of the organism, on improved diagnostic and prognostication tools, on defining risk factors for death, on optimal treatment strategies involving both antibiotics and adjunctive therapies, and on disease prevention. It is hoped that through these endeavors the outlook of pneumococcal infections will be improved.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.